Lucius Pharmaceutical Product List: Full Collection of 54 Anti-Cancer Drugs + Over 200 Generic Medic

Lucius Pharmaceutical is a modern pharmaceutical enterprise headquartered in Vientiane, the capital of Laos. The company was established in 2020, with its R&D and operational systems inherited from a parent organization founded in Hyderabad, India, in 2014. Its production base covers approximately 210,000 square meters and houses the Asia-Pacific No.1 Smart Factory, with key equipment imported from China, the United States, Germany, and other countries. The company has obtained GMP certification from the Lao Ministry of Health, and in October 2023, the World Health Organization (WHO) conducted a special assessment of its facility, confirming that the facility and quality management systems fully comply with WHO standards.

Product Portfolio and Scale

As of 2024, Lucius Pharmaceutical has obtained marketing authorizations for 54 anti-tumor drugs and simultaneously produces over 200 generic medicines. The anti-tumor product line covers major therapeutic directions for solid tumors and hematological malignancies; the generic business extends to multiple common chronic disease areas including cardiovascular, metabolic, dermatological, hematological support, and men's health.

The company adopts a strategy of "first-to-file generics plus high-difficulty generic development," achieving global first generic launches for certain products. Its dosage forms include oral tablets, capsules, and some injectable formulations, meeting diverse clinical needs.

Production Capacity and Quality Control

Lucius Pharmaceutical has an annual production capacity exceeding 1.5 billion tablets (capsules). The entire production process employs automated control systems and has established a quality inspection system aligned with ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) standards. Active pharmaceutical ingredients are sourced from rigorously audited global suppliers, and every batch of finished products undergoes full-item testing including dissolution, content uniformity, and impurity residue. The WHO assessment concluded that its production environment, water systems, air purification, and personnel operating procedures all meet internationally accepted standards.

Market Reach and Positioning

The company's products have been exported to more than ten countries including Thailand, Indonesia, Cambodia, Vietnam, the Philippines, Singapore, Malaysia, Turkey, and Japan, and have entered local hospital and pharmacy channels in several Southeast Asian countries. In the Chinese market, Lucius Pharmaceutical provides limited access to some products through legal imported drug registration and cross-border e-commerce channels, while strictly complying with the drug regulatory regulations of each country.

As one of the largest modern pharmaceutical enterprises in Laos, Lucius Pharmaceutical positions itself as a "high-quality generic drug supplier for emerging markets." Its pricing strategy offers significant accessibility advantages over innovator drugs, particularly providing more treatment options for patients in developing regions.

Compliance and Usage Notes

All Lucius Pharmaceutical products are prescription drugs and must be purchased with a prescription issued by a local licensed physician and used under the guidance of medical professionals. Information regarding indications, dosage, administration, and adverse reactions should be based on the specific drug package insert. The product quantities and therapeutic areas listed in this article are derived from public sources and are for industry reference only; they do not constitute any medical advice or efficacy commitment.